Nutriband Inc. has raised $1.8M as it works to combat the global opioid epidemic through innovative drug delivery systems.
The company, along with its clinical subsidiary 4P Therapeutics, has developed a technology called AVERSA, aimed at improving the safety of fentanyl and other opioid-based transdermal medications. Nutriband believes that with FDA approval, AVERSA could set a new safety standard for these treatments and save lives.


















